indazoles has been researched along with epidermal growth factor in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Chikh, A; Falasca, M; Maffucci, T; Raimondi, C; Wheeler, AP | 1 |
| Aceto, N; Auricchio, N; Barber, P; Baselga, J; Bergamaschi, A; Bosch, A; Carey, LA; Castel, P; Elkabets, M; Ellis, H; Hazra, S; Juric, D; Kim, P; Lewis, JS; Maheswaran, S; Morse, N; Ng, T; Penault-Llorca, F; Perou, CM; Radosevic-Robin, N; Scaltriti, M; Singh, S; Tao, JJ; Viola-Villegas, NT; Vojnovic, B; Weitsman, G | 1 |
| Adamski, H; Battistella, M; Bertucci, F; Da Meda, L; Dalac, S; Delyon, J; Ghrieb, Z; Guillot, B; Jouary, T; Lebbe, C; Leccia, MT; Meyer, N; Mortier, L; Mourah, S; Pedeutour, F; Porcher, R; Vicaut, E | 1 |
1 trial(s) available for indazoles and epidermal growth factor
| Article | Year |
|---|---|
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.
Topics: Adult; Aged; Biomarkers, Tumor; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Skin; Skin Neoplasms; Sulfonamides; Tumor Burden | 2021 |
3 other study(ies) available for indazoles and epidermal growth factor
| Article | Year |
|---|---|
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
A novel regulatory mechanism links PLCĪ³1 to PDK1.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Calcium; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Indazoles; Neoplasm Invasiveness; Phospholipase C gamma; Phosphorylation; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Signal Transduction; Transfection | 2012 |
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Blotting, Western; Cell Line, Tumor; Cetuximab; Dimerization; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Immunoglobulin G; Indazoles; Neuregulin-1; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms | 2014 |